Response to "hIV escape from RNAi antivirals: Yet another houdini action

Molecular Therapy Nucleic Acids

Volumn 1, Issue 6, 2012, Pages e28-

  Shah, Priya S ^a,c   Schaffer, David V ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868344430     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.23     Document Type: Letter

References (10)

1. Shah, PS, Pham, NP and Schaffer, DV (2012). HIV develops indirect cross-resistance to combinatorial RNAi targeting two distinct and spatially distant sites. Mol Ther 20: 840-848.
2. Leonard, JN, Shah, PS, Burnett, JC and Schaffer, DV (2008). HIV evades RNA interference directed at TAR by an indirect compensatory mechanism. Cell Host Microbe 4: 484-494.
3. Westerhout, EM, Ooms, M, Vink, M, Das, AT and Berkhout, B (2005). HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res 33: 796-804. (Pubitemid 40361009)
4. Wang, JK, Li, TX, Bai, YF and Lu, ZH (2003). Evaluating the binding affinities of NFkappaB p50 homodimer to the wild-type and single-nucleotide mutant Ig-kappaB sites by the unimolecular dsDNA microarray. Anal Biochem 316: 192-201. (Pubitemid 36452337)
5. Williams, SA, Chen, LF, Kwon, H, Ruiz-Jarabo, CM, Verdin, E and Greene, WC (2006). NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 25: 139-149. (Pubitemid 43077303)
6. Williams, SA, Kwon, H, Chen, LF and Greene, WC (2007). Sustained induction of NFkappa B is required for efficient expression of latent human immunodeficiency virus type 1. J Virol 81: 6043-6056. (Pubitemid 46847040)
7. Gallastegui, E, Marshall, B, Vidal, D, Sanchez-Duffhues, G, Collado, JA, Alvarez-Fernández, C et al. (2012). Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1. J Virol 86: 3795-3808.
8. Reuse, S, Calao, M, Kabeya, K, Guiguen, A, Gatot, JS, Quivy, V et al. (2009). Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS ONE 4: e6093.
9. Zhang, Z, Klatt, A, Gilmour, DS and Henderson, AJ (2007). Negative elongation factor NELF represses human immunodeficiency virus transcription by pausing the RNA polymerase II complex. J Biol Chem 282: 16981-16988. (Pubitemid 47093194)
10. ter Brake, O, Konstantinova, P, Ceylan, M and Berkhout, B (2006). Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther 14: 883-892. (Pubitemid 44743127)